EVAX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 121887 min ago

@ $4.00

Wydano: 13 vas. 2024 @ 22:29

Zwrot: -2.25%

Live Chart Being Loaded With Signals

Commentary (7 geg. 2024 @ 23:00):

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections...

Stats
Dzisiejszy wolumen	22 980.00
Średni wolumen	52 916.00
Kapitalizacja rynkowa	21.09M
EPS	$0 ( 2023-12-18 )
Następna data zysków	( $-0.550 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.0590 (1.56%)

Evaxion Biotech A/S Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Evaxion Biotech A/S Finanse

Annual	2023
Przychody:	$73 112.00
Zysk brutto:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2023
Przychody:	$73 112.00
Zysk brutto:	$73 112.00 (100.00 %)
EPS:	$-8.11

FY	2022
Przychody:	$0
Zysk brutto:	$-571 319 (0.00 %)
EPS:	$-9.80

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.514

Financial Reports:

No articles found.

Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.